A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma.

Trial Profile

A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Aug 2015

At a glance

  • Drugs Voxtalisib (Primary)
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 18 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 12 Sep 2014 Planned End Date changed from 1 Aug 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.
    • 12 Sep 2014 Planned primary completion date changed from 1 Aug 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top